MedTrace Logo

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

NCT05701007 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1083

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:

* What are the demographic and clinical characteristics of metastatic prostate cancer patients?
* How are metastatic prostate cancer patients currently treated and how effective are these treatments?
* How does the development of castration-resistance affect patient outcomes?
* What is the economic burden of metastatic prostate cancer?

Conditions

  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

abiraterone

mCRPC

DRUG

enzalutamide

mCRPC

DRUG

docetaxel

mCRPC

DRUG

apalutamide

mCRPC

DRUG

cabazitaxel

mCRPC

DRUG

Radium-223

mCRPC

DRUG

Lutetium-177

mCRPC

DRUG

degarelix

mCSPC

DRUG

goserelin

mCSPC

DRUG

leuprorelin

mCSPC

DRUG

triptorelin

mCSPC

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-13
Primary Completion
2024-04-10
Completion
2024-04-10

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701007 on ClinicalTrials.gov